Aurobindo Reprimanded By SEBI Over US FDA Warning Disclosure
‘Very Limited And Restricted Information’ Revealed By Indian Firm Deemed ‘Insufficient’
The Securities and Exchange Board of India says Aurobindo’s disclosures were not sufficient • Source: Shutterstock 
